Rostock/Berlin, Germany: CENTOGENE announces today a new sequencing facility for rare hereditary disorders, which will use Illumina’s HiSeq X® sequencer. With its well-established high-throughput facility for the early diagnosis of patients with rare diseases, CENTOGENE has reached the global next level of precision and data quality with the application of the whole genome sequencing (WGS) platform HiSeq X®.
CENTOGENE will be the first European company to use the groundbreaking next- generation sequencing (NGS) technology for the future generation of patient´s genomes in-house validated for diagnostic environment. With this step, CENTOGENE further solidifies its global position as one of the top medical institutions for the early and reliable diagnosis of rare hereditary disorders. The HiSeq X® system performs whole genome sequencing, producing industry-leading data at the most cost efficient way available in the market today. CENTOGENE also successfully became part of the Illumina Propel Certification Program for Core and Service Labs, certified for the HiSeq 4000, the MiSeq® and the NextSeq® technology, which defines a unique standard worldwide and proves the deep knowledge our scientific and medical experts developed and apply in the analytical testing processes.